PMC4901017_01
37-year-old male with MEN 1. The patient was injected with 24.8 mCi Tc-99m-labeled red blood cells, and images of the abdomen were acquired in the anterior projection for 90 minutes. Images show bleeding in the distribution of the small bowel during 61 to 75 minutes of imaging.
gr1.jpg
PMC4901017_01_gr1.jpg
fig1
Images show bleeding in the distribution of the small bowel (Fig. 1).
37-year-old male with MEN 1. The patient was injected with 25.8 mCi Tc-99m sestamib, i and images of the neck and chest in the anterior view were acquired at 10 minutes and at 2 hours. Early images (2A) show tracer uptake in both lobes of the thyroid gland, more prominent in the left mid thyroid and lower pole of right thyroid. Delayed images (2B) demonstrate a large persistent focus of increased radiotracer uptake in the mid left thyroid lobe and a smaller persistent focus of increased radiotracer uptake in the lower pole of the right thyroid lobe. Two questionable foci of less intense persistent tracer uptake also appear in the upper pole of the right thyroid lobe and the lower pole of the left thyroid lobe. Findings are consistent with multiple parathyroid adenomas or parathyroid hyperplasia.
gr2.jpg
PMC4901017_01_gr2.jpg
fig2ab
Findings were consistent with multiple parathyroid adenomas or parathyroid hyperplasia (Fig. 2).
37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 4 hours (3A) and 24 hours (3B). SPECT images were also obtained at 24 hours (3C, axial, and 3D, coronal). Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region. In addition, diffusely increased radiotracer uptake in the neck likely corresponds to the parathyroid pathology seen on the prior parathyroid scan.
gr3.jpg
PMC4901017_01_gr3.jpg
fig3ad
The patient also underwent an octreotide scan; results were consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes in the porta hepatis region (Fig. 3).